|
|
Volumn 14, Issue 9, 2015, Pages 589-591
|
|
Stem-cell discovery platforms yield first clinical candidates
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMYLOID BETA PROTEIN;
BMS 986168;
PLACEBO;
PRESENILIN 1;
PROTEIN ANTIBODY;
RETIGABINE;
RG 7800;
TAU PROTEIN;
UNCLASSIFIED DRUG;
ALZHEIMER DISEASE;
AMYOTROPHIC LATERAL SCLEROSIS;
ARTICLE;
CLINICAL DECISION MAKING;
COST EFFECTIVENESS ANALYSIS;
DRUG IDENTIFICATION;
DRUG INDUSTRY;
DRUG RESEARCH;
DRUG SAFETY;
DRUG SCREENING;
EPILEPSY;
EYE TOXICITY;
HUMAN;
NONHUMAN;
NUCLEAR REPROGRAMMING;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PLURIPOTENT STEM CELL;
PRIORITY JOURNAL;
PROGRESSIVE SUPRANUCLEAR PALSY;
SPINAL MUSCULAR ATROPHY;
STEM CELL RESEARCH;
TAUOPATHY;
TREATMENT OUTCOME;
CLINICAL TRIAL (TOPIC);
PROCEDURES;
STEM CELL TRANSPLANTATION;
TRANSPLANTATION;
TRENDS;
CLINICAL TRIALS AS TOPIC;
DRUG INDUSTRY;
HUMANS;
INDUCED PLURIPOTENT STEM CELLS;
STEM CELL TRANSPLANTATION;
|
|
EID: 84940871746
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4708 Document Type: Article |
|
Times cited : (32)
|
|
References (0)
|
